Exploring skeletal muscle tolerance and whole‐body metabolic effects of FDA‐approved drugs in a volumetric muscle loss model

Volumetric muscle loss (VML) is associated with persistent functional impairment due to a lack of de novo muscle regeneration. As mechanisms driving the lack of regeneration continue to be established, adjunctive pharmaceuticals to address the pathophysiology of the remaining muscle may offer partia...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijwadia, Shefali R., Raymond‐Pope, Christiana J., Basten, Alec M., Lentz, Mason T., Lillquist, Thomas J., Call, Jarrod A., Greising, Sarah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277213/
https://www.ncbi.nlm.nih.gov/pubmed/37332022
http://dx.doi.org/10.14814/phy2.15756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277213/
https://www.ncbi.nlm.nih.gov/pubmed/37332022
http://dx.doi.org/10.14814/phy2.15756

Ejemplares similares